Key Highlights
- Aleniglipron, Structure Therapeutics’ oral GLP-1 medication, achieved 16.3% placebo-adjusted weight reduction after 44 weeks in the ACCESS II Phase 2 study
- The performance exceeded oral GLP-1 competitors from Eli Lilly (12.4%) and Novo Nordisk (13.6%) in their respective Phase 2 trials
- Data indicated continuous weight reduction with no plateau effect, distinguishing it from competing treatments
- Shares of GPCR climbed approximately 10% on Monday, reaching $59.80 following the announcement
- The company anticipates an FDA end-of-Phase 2 consultation in Q2 2026, with Phase 3 trials launching in H2 2026
Structure Therapeutics unveiled impressive Phase 2 clinical results for aleniglipron, its oral GLP-1 obesity medication, on Monday, propelling GPCR shares upward by roughly 10% during morning market activity.
Structure Therapeutics Inc., GPCR
The ACCESS II clinical study demonstrated placebo-adjusted weight reduction of 16.3% with the 180 mg dosage and 16.0% with the 240 mg dosage following 44 weeks of treatment. Importantly, neither dosage level exhibited any plateau pattern.
These findings stack up favorably against competitor medications. Novo Nordisk’s oral version of Wegovy registered 13.6% weight reduction in Phase 3 testing. Eli Lilly’s orforglipron demonstrated approximately 12.4% in Phase 2 trials and 11.2% in Phase 3.
Previously released December data had revealed 14.2% weight reduction at a reduced dose. Subjects who continued with that initial lower dose for 53 weeks ultimately achieved 16% weight reduction, demonstrating sustained efficacy over extended periods.
Safety and tolerability metrics also proved favorable. The ACCESS Open Label Extension trial recorded only a 2% discontinuation rate due to adverse events. The body composition analysis showed a 3.4% rate. Structure’s strategy of initiating treatment at a low 2.5 mg dose appears instrumental in supporting patient adherence.
The positive outcomes have sparked acquisition speculation. H.C. Wainwright’s analyst Ananda Ghosh had previously identified aleniglipron this month as “the most acquirable asset in obesity.” The investment firm increased its price objective to $114. Citizens maintained its Market Outperform designation while adjusting its target to $113.
Wall Street Response
Leerink Partners maintained its Outperform rating and $90 price objective following the data release. The investment firm emphasized the favorable tolerability profile and clear dose-response correlation as significant advantages.
RBC Capital Markets adopted a more cautious stance. Analyst Trung Huynh observed that orforglipron showed comparable Phase 2 performance before declining in Phase 3 results. He identified an atypically minimal weight gain in the placebo cohort as a statistical anomaly warranting attention. RBC maintained its Outperform rating on Lilly with a $1,250 price objective.
“It’s difficult to characterize these results as meaningfully differentiated from Orfo or oral Wegovy until we get a more robust data set,” Huynh wrote.
Looking Ahead
Structure Therapeutics intends to conduct an end-of-Phase 2 consultation with the FDA during Q2 2026. Phase 3 trials are projected to commence in the latter half of 2026. The Phase 2 findings from both elevated doses will guide the selection of which dose advances to late-stage development.
Despite Monday’s gains, the stock remains down 23% year-to-date, though it has surged 155% over the trailing twelve months. Trading at $59.80, the stock remains substantially below Wall Street consensus price objectives, which span from $90 to $140.
Cantor Fitzgerald had earlier identified this 44-week data release as a significant potential catalyst for share performance. That projection materialized accurately.
Monday’s rally elevated GPCR’s market capitalization to roughly $3.81 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
